Brucellosis is a zoonotic disease that poses a serious threat to public health and safety. Although the live attenuated vaccines targeting brucellosis, such as M5‑90, are effective, there are a number of drawbacks to their use. For example, the vaccines are unable to differentiate between the natural and vaccinated forms of the infection, and these vaccines have also been shown to cause abortion in pregnant animals. Therefore, a safer and more potent vaccine is required. In the present study, a B. melitensis 16M TcfSR promoter mutant (16MΔTcfSR) was constructed in an attempt to overcome these drawbacks. A TcfSR mutant was derived from B. melitensis 16M and tested for virulence and protection efficiency. Levels of immuoglobulin G (IgG), and cytokine production were determined. In addition, TcfS was assessed as a diagnostic marker for brucellosis. The survival capacity of the 16MΔTcfSR mutant was shown to be attenuated in the RAW 264.7 murine macrophage cell line and BALB/c mice, and the vaccination was shown to induce a high level of protective immunity in BALB/c mice. In addition, the 16MΔTcfSR vaccination elicited an anti‑Brucella‑specific IgG response and induced the secretion of interferon‑γ. Thus, the TcfS antigen allowed for the serological differentiation between the natural and vaccinated infection in animals. In conclusion, the results demonstrated that the 16MΔTcfSR mutant was attenuated in murine macrophage cells and BALB/c mice; therefore, 16MΔTcfSR is a potential candidate for a live attenuated vaccine against B. melitensis infection.
Background: Salmonella Typhimurium poses a substantial health risk to both humans and animals. This study evaluated the potential of using the Salmonella Typhimurium ΔsptP mutant as a live-attenuated vaccine candidate by constructing it through homologous recombination and assessing its key biological properties, including growth characteristics, immunogenicity, and protective efficacy. Methods: We generated the ΔsptP mutant through targeted gene deletion, ensuring the preservation of the bacterial strain’s growth and stability. In vitro and in vivo assays were performed to compare the invasive capabilities between the mutant and the wild-type strains. Specifically, we examined the invasion into RAW264.7 murine macrophages and mice. Furthermore, the virulence of the mutant was evaluated by determining the median lethal dose (LD50). To evaluate immunogenicity and protection, mice were immunized with 2 × 104 CFUs of the ΔsptP mutant, followed by a booster immunization, and then challenged with a virulent strain. Results: The ΔsptP mutant exhibited no significant changes in growth characteristics or genetic stability compared to the wild-type strain. However, it demonstrated a significantly diminished capacity for invasion in both murine macrophages and mice. The LD50 for the mutant was 39.92-fold higher than that of the wild-type, indicating a marked reduction in virulence. Mice immunized with the ΔsptP mutant and administered a booster immunization exhibited 87.5% protection against challenge with a virulent strain, as compared to the PBS control group. Moreover, the mutant induced IgG antibody levels comparable to those induced by the wild-type strain. Conclusions: The ΔsptP mutant of Salmonella Typhimurium exhibits markedly reduced virulence while retaining robust immunogenicity and protective efficacy. These findings suggest that the ΔsptP mutant is a promising candidate for a live-attenuated vaccine, potentially providing an effective strategy to prevent Salmonella Typhimurium infections.
Salmonella typhimurium is a pathogen that poses a severe health risk to humans and animals. We discussed the feasibility of the Salmonella typhimurium ΔsptP mutant as a live attenuated vaccine, constructed a Salmonella typhimurium ΔsptP mutant by homologous recombination, and evaluated its biological functions, such as growth characteristics, immunogenicity, and protective properties. We found that the ΔsptP gene mutant of Salmonella typhimurium is a safe and effective live attenuated vaccine. The mutation of the sptP gene does not affect the growth and character of bacteria and has genetic stability. Compared with wild-type Salmonella typhimurium, the colonization ability of the mutant in RAW264.7 mouse macrophages and mice was significantly weakened. The median lethal dose (LD50) of the ΔsptP mutant was 39.92 times that of the wild-type strain, indicating that the virulence of the ΔsptP mutant was significantly weakened. After inoculation with 2×104 CFU ΔsptP mutant and one booster immunization, the mice were able to resist 87.5% of the virulent strains compared to the PBS control group, and the level of IgG antibodies produced by the mutant was similar to that of the wild-type strain. These results show that ΔsptP mutants of Salmonella typhimurium are significantly less virulent to mice than wild-type strains. The sptP mutant is immunogenic and protective in mice, and ΔsptP can be used as a live attenuated vaccine for Salmonella typhimurium disease.